Impact of a reduced error range of SMBG in insulin-treated patients in Germany

Journal of Diabetes Science and Technology

Volumn 8, Issue 3, 2014, Pages 479-482

  Schnell, Oliver ^a   Erbach, Michael ^b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b Sciarc Institut   (Germany)

Author keywords

Accuracy; Cost analysis; Diabetes; Hypoglycemia; Self monitoring of blood glucose

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ARTICLE; BLOOD GLUCOSE METER; BLOOD GLUCOSE MONITORING; COST CONTROL; DIABETIC PATIENT; DIAGNOSTIC TEST ACCURACY STUDY; GERMANY; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MEASUREMENT ERROR; BLOOD; CHEMICALLY INDUCED; DEVICES; DIABETES MELLITUS, TYPE 1; DRUG COST; DRUG EFFECTS; ECONOMIC MODEL; ECONOMICS; METABOLISM; PREDICTIVE VALUE; REPRODUCIBILITY; TREATMENT OUTCOME;

BIOMARKERS; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; COST SAVINGS; DIABETES MELLITUS, TYPE 1; DRUG COSTS; GERMANY; HEALTH CARE COSTS; HEALTH EXPENDITURES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MODELS, ECONOMIC; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 84900801034     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/1932296813516206     Document Type: Article

References (19)

1. Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575-1585.
2. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-2572. (Pubitemid 351831357)
3. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-139.
4. American Diabetes Association. Standards of medical care in diabetes - 2012. Diabetes Care. 2012;35(suppl 1):S11-S63.
5. Kovatchev BP, Otto E, Cox D, Gonder-Frederick L, Clarke W. Evaluation of a new measure of blood glucose variability in diabetes. Diabetes Care. 2006;29(11):2433-2438. (Pubitemid 44912248)
6. Schnell OAH, Battelino T, Ceriello A, et al. Consensus statement on self-monitoring of blood glucose in diabetes: a European perspective. Diab Metabol Heart. 2009;18:285-289.
7. Peel E, Parry O, Douglas M, Lawton J. Blood glucose self-monitoring in non-insulin-treated type 2 diabetes: a qualitative study of patients' perspectives. Br J Gen Pract. 2004;54(500):183-188. (Pubitemid 38279488)
8. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
9. Schnell O, Erbach M, Wintergerst E. Higher accuracy of self-monitoring of blood glucose in insulin-treated patients in Germany: clinical and economical aspects. J Diabetes Sci Technol. 2013;7(4):904-912.
10. International Organization for Standardization. In Vitro Diagnostic Test Systems - Requirements for Blood-glucose Monitoring Systems for Self-testing in Managing Diabetes Mellitus. EN ISO/DIS 15197:2013. Available at: http://www.iso.org/iso/home/store/catalogue-tc/catalogue-detail.htm?csnumber= 54976.
11. International Organization for Standardization. In Vitro Diagnostic Test Systems - Requirements for Blood-glucose Monitoring Systems for Self-testing in Managing Diabetes Mellitus. ISO 15197: 2003. Available at: http://www.iso.org/ iso/home/store/catalogue-tc/catalogue-detail.htm?csnumber=26309.
12. Budiman ES, Samant N, Resch A. Clinical implications and economic impact of accuracy differences among commercially available blood glucose monitoring systems. J Diabetes Sci Technol. 2013;7(2):365-380.
13. Breton MD, Kovatchev BP. Impact of blood glucose self-monitoring errors on glucose variability, risk for hypoglycemia, and average glucose control in type 1 diabetes: an in silico study. J Diabetes Sci Technol. 2010;4(3):562-570.
14. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008;31(8):1473-1478.
15. Diabetes Control and Complications Trial Research Group. Hypoglycemia in the diabetes control and complications trial. Diabetes. 1997;46(2):271-286.
16. UKPDS Risk Engine. Available at: http://www.dtu.ox.ac.uk/riskengine/. Accessed September 6, 2013.
17. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643-2653. (Pubitemid 41817713)
18. Jonsson L, Bolinder B, Lundkvist J. Cost of hypoglycemia in patients with type 2 diabetes in Sweden. Value Health. 2006;9(3):193-198.
19. Davis RE, Morrissey M, Peters JR, Wittrup-Jensen K, Kennedy-Martin T, Currie CJ. Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes. Curr Med Res Opin. 2005;21(9):1477-1483. (Pubitemid 41368581)